Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | EED | O75530 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 5/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7771023 | 0.93 | SIGMAR1 (0.46) | SIGMAR1CHRNB2CHRNA4EEDATR | |
| SCHEMBL7766918 | 0.85 | SIGMAR1 (0.42) | SIGMAR1CHRNB2CHRNA4MMP9NAMPT | |
| SCHEMBL25522265 | 0.85 | SIGMAR1 (0.42) | SIGMAR1CHRNB2CHRNA4MMP9EED | |
| SCHEMBL9965975 | 0.77 | MAOA (0.59) | SIGMAR1CHRNB2CHRNA4EED | |
| SCHEMBL861951 | 0.76 | MAOA (0.57) | EED | |
| SCHEMBL20078475 | 0.74 | MAOA (0.55) | — | |
| SCHEMBL23868391 | 0.74 | PDGFRB (0.32) | SIGMAR1ATRNAMPTPDGFRBKDR | |
| SCHEMBL19619569 | 0.74 | NAMPT (0.40) | SIGMAR1CHRNB2CHRNA4NAMPT | |
| SCHEMBL20159085 | 0.74 | SIGMAR1 (0.61) | SIGMAR1CHRNB2CHRNA4 | |
| SCHEMBL18630000 | 0.73 | SIGMAR1 (0.50) | SIGMAR1CHRNB2CHRNA4EEDNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230144581-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230025932-A1 | NOVEL FUNCTIONALIZED LACTONES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2023-01-26 | — | — | US | disclosed |
| US-20230002383-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2023-01-05 | — | — | US | disclosed |
| US-11071721-B2 | Bicyclic amide compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-10933036-B2 | — | — | 2021-03-02 | — | — | US | disclosed |
| US-20180153831-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153831-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8263598-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090186899-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317644-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | SIGMAR1 143/4885CHRNB2 4415/4885CHRNA4 4328/4885 |
| US-20180153831-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | CYP4B1, CYP1B1, AADAC | SIGMAR1 251/4885CHRNB2 3285/4885CHRNA4 3127/4885 |
| US-11071721-B2 | Bicyclic amide compounds and methods of use thereof | CYP4B1, CYP1B1, AADAC | SIGMAR1 251/4885CHRNB2 3285/4885CHRNA4 3127/4885 |
| US-20090186899-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | SIGMAR1 103/4885CHRNB2 873/4885CHRNA4 1048/4885 |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | SIGMAR1 1349/4885CHRNB2 4798/4885CHRNA4 4724/4885 |
| US-10933036-B2 | — | CYP1B1, CYP4B1, CYP11B2 | SIGMAR1 220/4885CHRNB2 2486/4885CHRNA4 3087/4885 |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | RAD51, FANCI, BLM | SIGMAR1 3648/4885CHRNB2 3715/4885CHRNA4 4466/4885 |
| US-20230144581-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | SIGMAR1 1101/4885CHRNB2 36/4885CHRNA4 248/4885 |
| US-20230025932-A1 | NOVEL FUNCTIONALIZED LACTONES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR2C, HTR3A | SIGMAR1 91/4885CHRNB2 159/4885CHRNA4 223/4885 |
| US-20230002383-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR1A, HTR2C | SIGMAR1 38/4885CHRNB2 151/4885CHRNA4 196/4885 |
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | SIGMAR1 369/4885CHRNB2 636/4885CHRNA4 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.